ProKidney Corp.
Elizabeth Lotz is an accomplished professional in clinical operations, currently serving as the Senior Director of Clinical Operations at ProKidney Corp. and previously holding similar roles at SystImmune, Novotech, and NCGS, Inc., where responsibilities escalated from Senior Project Manager to Director of Clinical Operations. Early career experience includes a Project Manager position at Angiotech Pharmaceuticals. Elizabeth Lotz earned degrees from the Medical University of South Carolina and The Citadel, reinforcing a solid educational foundation in the field.
This person is not in any teams
This person is not in any offices
ProKidney Corp.
ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.